PMID- 22672151
OWN - NLM
STAT- MEDLINE
DCOM- 20130320
LR  - 20190221
IS  - 1464-410X (Electronic)
IS  - 1464-4096 (Linking)
VI  - 111
IP  - 2
DP  - 2013 Feb
TI  - A national study of adverse effects and global quality of life among candidates 
      for curative treatment for prostate cancer.
PG  - 221-32
LID - 10.1111/j.1464-410X.2012.11198.x [doi]
AB  - OBJECTIVES: To provide population-based estimates of typical adverse effects 
      (AEs), e.g. urinary, bowel and sexual dysfunction, in patients with 
      non-metastatic recurrence-free prostate cancer (PCa) by curative treatment 
      method, including no treatment. To describe associations between typical AEs and 
      global quality of life (QoL) and to study patients' use of medication for 
      erectile dysfunction (EDmed) and the relationship between such use and global 
      QoL. PATIENTS AND METHODS: In October 2006 a national population-based sample of 
      PCa survivors diagnosed in 2004 was invited to a postal survey focusing on 
      treatment-related AEs and global QoL, 12-32 months after treatment start. All had 
      completed their initial treatment. In the present study, 771 compliers were 
      categorized into four groups of localized or locally advanced PCa related to the 
      treatment they completed: (i) no treatment; (ii) radical prostatectomy (RP); 
      (iii) radiotherapy (RAD) without hormones; and (iv) RAD with hormone therapy of 
      3-24 months duration. Measurement of AEs was restricted to function, using 
      selected items from the 50-item Expanded Prostate Cancer Index Composite and the 
      Brief Sexual Function Inventory among others, whereas global QoL was measured 
      with the 12-item short-form health survey. National prescription data enabled 
      assessment of adjuvant hormone application and EDmed use. RESULTS: Men who had 
      undergone RP reported more urinary incontinence (24%) than the other treatment 
      groups, but had the lowest level of moderate/severe urinary 
      irritative-obstructive symptoms. Men from the 'no treatment' group had the 
      highest level of moderate/severe irritative-obstructive urinary symptoms. Men who 
      had undergone RAD reported higher levels of irritative intestinal symptoms and 
      faecal leakage compared with the RP group and the no treatment group. In all 
      treatment groups, poor sexual drive and poor erectile function were common AEs, 
      with men treated with RP reporting the highest prevalence of poor erectile 
      function (89%). Presence of irritative-obstructive urinary symptoms and poor 
      sexual drive were independently associated with low global QoL in multivariate 
      analyses. Fifty percent of the study group had used EDmed after treatment start, 
      but only 47% of them were still using EDmed at the time of the survey. Use of 
      EDmed was not significantly associated with global QoL. CONCLUSIONS: PCa 
      survivors after curative treatment, but also patients without any anticancer 
      therapy, report high levels of urinary and sexual AEs. Irritative-obstructive 
      urinary symptoms and poor sexual drive were significantly associated with low 
      global QoL, whereas erectile function and use of EDmed were not.
CI  - (c) 2012 The Authors. BJU International (c) 2012 BJU International.
FAU - Kyrdalen, Anne E
AU  - Kyrdalen AE
AD  - Department of Oncology, Oslo University Hospital, Norway. aed@ous-hf.no
FAU - Dahl, Alv A
AU  - Dahl AA
FAU - Hernes, Eivor
AU  - Hernes E
FAU - Smastuen, Milada Cvancarova
AU  - Smastuen MC
FAU - Fossa, Sophie D
AU  - Fossa SD
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120606
PL  - England
TA  - BJU Int
JT  - BJU international
JID - 100886721
RN  - 0 (Androgen Antagonists)
RN  - 0 (Delayed-Action Preparations)
RN  - 33515-09-2 (Gonadotropin-Releasing Hormone)
SB  - IM
CIN - J Urol. 2012 Dec;188(6):2316-7. PMID: 23141267
MH  - Aged
MH  - Androgen Antagonists/adverse effects
MH  - Anxiety Disorders/*etiology
MH  - Chemotherapy, Adjuvant/adverse effects
MH  - Combined Modality Therapy/adverse effects
MH  - Delayed-Action Preparations
MH  - Erectile Dysfunction/etiology
MH  - Fecal Incontinence/etiology
MH  - Gonadotropin-Releasing Hormone/administration & dosage/adverse effects
MH  - Health Surveys
MH  - Humans
MH  - Intestinal Diseases/etiology
MH  - Libido
MH  - Male
MH  - Middle Aged
MH  - Neuroticism
MH  - Prostatectomy/adverse effects
MH  - Prostatic Neoplasms/psychology/*therapy
MH  - *Quality of Life
MH  - Risk Factors
MH  - Urinary Incontinence/etiology
EDAT- 2012/06/08 06:00
MHDA- 2013/03/21 06:00
CRDT- 2012/06/08 06:00
PHST- 2012/06/08 06:00 [entrez]
PHST- 2012/06/08 06:00 [pubmed]
PHST- 2013/03/21 06:00 [medline]
AID - 10.1111/j.1464-410X.2012.11198.x [doi]
PST - ppublish
SO  - BJU Int. 2013 Feb;111(2):221-32. doi: 10.1111/j.1464-410X.2012.11198.x. Epub 2012 
      Jun 6.